Currently, over 110 independent groups and research teams around the world are in the process of finding a potential vaccine or treatment for the new coronavirus strain. Of these, more than 10 have received approved approvals and several positive clinical trials are also taking place in countries.
Favipiravir, known in the medical community as T-705 or Avigan, is a drug that has previously been used to fight the outbreak of influenza in Japan and other viral diseases. The announcement comes after another pharmaceutical company, Glenmark, became the first company to receive Favipiravir dosing in the country.
Glenmark, which is already testing the use of Favipiravir, is completing Phase 3 of its trials and expects to see more results between July and August.
Although there are many studies to be done, Favipiravir is potentially being researched as one effective medicine for coronavirus.
How does Favipiravir work?
Favipiravir, used to fight a variety of viral-borne diseases, was earmarked as an anti-flu drug in 2014. In some parts of Japan, the drug was also investigated and used experimentally to treat the Ebola crisis, which was another pandemic we witnessed.
Favipiravir has also been used in recent months in China by medical authorities who found that the drug is “effective” and “safe” for the treatment of coronavirus. Early studies in China found that COVID-positive patients administered a dose of this drug tested negative for a four-day period and 91% of cases showed promising lung improvement in X-ray examinations. In Japan, where the cases are also growing, the drug is used for patients with mild or moderate symptoms to stop the multiplication of the rapidly spreading viral disease. However, it is interesting that the parent company’s confirmations are not confirmed by the drug association.
Favipiravir, T-705 is an anti-viral agent that targets the RNA polymerase chain of RNA viruses, such as coronaviruses and prevents it from replicating inside the body. It is also effective in eradicating certain strains of mutant influenza viruses, other than other RNA viruses, such as bunyaviruses, filoviruses, which may have life-threatening implications. Because of these, the researchers are convinced that if given at the right dose, Favipiravir can be extremely helpful in fighting and treating new coronavirus.
Although it has shown good results in some cases where the symptoms are mild or transient, one of the limitations of the drug appears to be its work on patients who exhibit severe symptoms. A Japanese health worker also commented and spoke about the same:
“We’ve given Avigan 70 to 80 people, but it doesn’t seem to work as well when the virus has already been multiplied,”